170
Views
1
CrossRef citations to date
0
Altmetric
Research Articles

Human wharton-jelly mesenchymal stromal cells reversed apoptosis and prevented multi-organ damage in a newborn model of experimental asphyxia

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 3568-3576 | Received 30 Apr 2022, Accepted 09 Dec 2022, Published online: 13 Jan 2023
 

Abstract

In this study, the effect of applying wharton jelly mesenchymal stromal cells (WJ-MSC) isolated from the human umbilical cord tissue on the neonatal mouse model caused experimental asphyxia in mice was investigated. WJ-MSC surface markers (CD44, CD90, CD105) were characterised by immunofluorescence staining, and pluripotency genes (Nanog, Oct-4, Sox-2) were characterised by qPCR. Blood, prefrontal cortex, cerebellum, hippocampus, lung, heart, kidney, and liver tissues were analysed twenty days after subcutaneously administered WJ-MSC. WJ-MSC administration significantly decreased serum TNF-α, NSE, GFAP, and IL-6 levels in the asphyxia mice. It was determined that WJ-MSC application in tissues accelerated cell regeneration and decreased oxidative stress. In conclusion, this study showed that multiorgan damage in asphyxia could be prevented by applying WJ-MSC at an early stage. Therefore, WJ-MSC application in infants with neonatal asphyxia in the clinic may be an innovative method in the future.

Graphical Abstract

The umbilical cord was taken from human caesarean section and separated wharton jelly (WJ). WJ applied the enzymatic degradation by collagenase type 1. Mesenchymal stromal cells (MSC) isolated from WJ and characterised by CD90, CD105, and CD44 cell surface receptors staining. Newborn Balb/c mice taken by caesarean section on day 18th were placed in chambers and exposed to 4% O2, 20% CO2, and 76% N2 gas to hypoxic conditions for asphyxia. WJ-MSC (2 × 106 cells) were administered subcutaneously to asphyxiated mice every five days for 20 days (n = 7). Multiple organ damage was performed on prefrontal cortex, cerebellum, hippocampus, heart, lung, kidney, and liver tissues using biological and histological assays.

The umbilical cord was taken from human caesarean section and separated wharton jelly (WJ). WJ applied the enzymatic degradation by collagenase type 1. Mesenchymal stromal cells (MSC) isolated from WJ and characterised by CD90, CD105, and CD44 cell surface receptors staining. Newborn Balb/c mice taken by caesarean section on day 18th were placed in chambers and exposed to 4% O2, 20% CO2, and 76% N2 gas to hypoxic conditions for asphyxia. WJ-MSC (2 × 106 cells) were administered subcutaneously to asphyxiated mice every five days for 20 days (n = 7). Multiple organ damage was performed on prefrontal cortex, cerebellum, hippocampus, heart, lung, kidney, and liver tissues using biological and histological assays.

    IMPACT STATEMENT

  • What is already known on this subject? Perinatal asphyxia is a serious condition that generates progressive neurological defects and systemic multi-organ failure because of the absence of blood flow or gas exchange in the fetusfoetus during birth. There is no clinical application to reduce damage except for hypothermia treatment in asphyxia.

  • What do the results of this study add? This study showed that WJ-derived mesenchymal stromal cell administration could be used to treat hypoxia-induced asphyxia in newborns. In addition, it can be effective against multi-organ damage caused by asphyxia by evaluating the rich content of the UC tissue expelled during birth.

  • What are the implications of these findings for clinical practice and/or further research? In treating asphyxia, the need to develop new strategies emerges as these are not effective in reducing the damage adequately. This WJ-MSC will be new hope for treating asphyxia and guide clinical applications.

Acknowledgments

We thank ODC Research and Development Inc for their support in cell culture materials.

Additional information

Funding

This work was supported by Aydin Adnan Menderes University Research Grant (ADU-TPF-20020).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.